Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B.
Pretreatment of mice with the potent and selective monoamine oxidase B (MAO-B) inhibitor MDL 72145 ((E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine) protected against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Mice treated with MDL 72145 prior to MPTP did not exhibit the decrement in the neostriatal content of dopamine and its metabolites normally seen after MPTP administration. This observation adds further support to the concept that the oxidation of MPTP by MAO-B to its corresponding pyridinium analog, 1-methyl-4-phenylpyridinium (MPP+), is an important feature of the neurotoxic process.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000499:Allylamine / Q000031:analogs & derivatives / Q000494:pharmacology*; D000588:Amines / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000201:enzymology*; D003010:Clorgyline / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D008297:Male; D051379:Mice; D008928:Mitochondria / Q000201:enzymology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D011725:Pyridines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D012642:Selegiline / Q000494:pharmacology
D000588:Amines; D008996:Monoamine Oxidase Inhibitors; D011725:Pyridines; D012642:Selegiline; D000499:Allylamine; C040051:2-(3,4-dimethoxyphenyl)-3-fluoroallylamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D003010:Clorgyline; D004298:Dopamine